Integer Holdings Corporation ITGR R2KR3KPHARMA
Company Overview
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.85B (+8.0% YoY); net profit $102.81M.
- Trailing 12 Months Year-on-year growth — revenue -2.6%, earnings -33.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 1.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.82% |
| 1 Year: | -2.60% |
Compounded Profit Growth
| 5 Years: | 1.31% |
| 1 Year: | -33.70% |
Stock Price Performance
| 1 Year: | +15.44% |
| 6 Months: | +50.54% |
| 3 Months: | +37.53% |
| 1 Month: | +0.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)82.01 · Overbought
P/E of 34.56 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 82 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ITGR Integer Holdings Corporation R2KR3KPHARMA | 126.50 | 34.56 | $4.30B | 0.00% | 7.52% | 7.50% | 8.82% | 1.31% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 266.74M | 280.92M | 286.17M | 302.26M | 292.43M | 314.46M | 305.09M | 303.03M | 314.68M | 314.19M | 303.59M | 325.64M | 328.43M | 240.12M | 235.94M | 268.96M | 290.47M | 312.02M | 305.57M | 310.91M | 350.08M | 342.68M | 378.79M | 400.04M | 396.80M | 407.80M | 427.89M | 431.42M | 437.39M | 476.49M | 467.69M | 439.58M | 464.11M |
| Gross Profit | 57.95M | 51.65M | 73.14M | 91.47M | 96.03M | 97.91M | 92.89M | 82.03M | 89.17M | 89.19M | 93.62M | 83.53M | 98.77M | 91.92M | 88.44M | 88.61M | 96.98M | 93.39M | 76.03M | 96.70M | 57.86M | 57.93M | 73.21M | 84.49M | 88.75M | 81.87M | 81.47M | 92.90M | 86.72M | 96.67M | 105.80M | 104.99M | 108.27M | 117.38M | 116.57M | 120.32M | 129.15M | 126.16M | 109.59M | 112.94M |
| Operating Income | 13.03M | 1.20M | - | 11.13M | 29.27M | 36.86M | - | 26.55M | 36.06M | 35.83M | - | 30.04M | 44.36M | 41.46M | - | 39.17M | 49.34M | 46.48M | - | 44.08M | 9.19M | 39.76M | - | 34.61M | 39.35M | 33.09M | 22.50M | 32.71M | 29.26M | 34.17M | 41.58M | 48.78M | 38.70M | 54.49M | 58.01M | 49.55M | 59.34M | 56.44M | 31.87M | 34.53M |
| Net Income | 9.28M | 22.00K | -24.91M | -12.66M | -770.00K | 11.46M | 7.93M | 2.95M | 9.56M | 19.88M | 54.70M | 13.08M | 23.06M | -8.30M | 19.20M | 21.67M | 33.06M | 30.59M | 11.04M | 31.10M | 389.00K | 30.34M | - | 21.52M | 29.43M | 22.07M | 11.37M | 20.84M | 16.06M | 13.06M | 23.97M | 27.26M | 20.51M | 31.25M | 35.44M | -22.49M | 37.01M | 39.68M | 16.51M | 23.61M |
| Diluted EPS | 0.35 | 0.00 | -0.85 | -0.41 | -0.03 | 0.37 | 0.25 | 0.09 | 0.30 | 0.62 | 1.69 | 0.40 | 0.70 | -0.26 | 0.58 | 0.65 | 0.85 | 0.92 | 0.33 | 0.94 | 0.01 | 0.92 | 0.47 | 0.65 | 0.89 | 0.66 | 0.34 | 0.62 | 0.48 | 0.39 | 0.71 | 0.81 | 0.59 | 0.88 | 0.99 | -0.66 | 1.04 | 1.11 | 0.48 | 0.69 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 521.82M | 533.42M | 568.82M | 646.18M | 663.95M | 687.79M | 800.41M | 1.08B | 1.14B | 1.22B | 1.26B | 1.07B | - | 1.33B | 1.56B | 1.72B | 1.85B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 985.52M | 1.15B | 1.26B | 1.35B |
| Gross Profit | 166.42M | 173.58M | 180.35M | 201.65M | 219.31M | 231.40M | 235.13M | 337.68M | 354.01M | 362.67M | 355.01M | 285.71M | - | 345.76M | 409.89M | 459.01M | 500.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 217.81M | 235.14M | 238.63M | 261.25M |
| Operating Income | 1.05M | 68.99M | 61.70M | 25.82M | 61.34M | 75.65M | 13.15M | 92.92M | 125.65M | 155.56M | 157.63M | 120.61M | - | 127.95M | 174.75M | 220.39M | 239.14M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 197.93M | 255.50M | 310.91M | 292.39M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.27M | 51.27M | 52.32M | 36.32M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 68.68M | 105.38M | 147.56M | 125.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.93M | 16.24M | 26.51M | 22.57M |
| Net Income | -9.00M | 33.14M | 33.12M | -4.80M | 36.27M | 55.46M | -7.59M | 5.96M | 66.68M | 167.96M | 96.34M | 77.26M | - | 66.38M | 90.65M | 119.90M | 102.81M |
| Diluted EPS | -0.39 | 1.40 | 1.40 | -0.20 | 1.43 | 2.14 | -0.29 | 0.19 | 2.08 | 5.15 | 2.92 | 2.33 | - | 1.99 | 2.69 | 3.36 | 2.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2009 | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 776.98M | 881.35M | 889.88M | 889.63M | 955.12M | 2.98B | 2.83B | 2.85B | 2.33B | 2.35B | 2.37B | 2.58B | 2.79B | 2.94B | 3.08B | 3.41B |
| Total Equity | 374.79M | 379.72M | 426.83M | 467.28M | 480.86M | 542.05M | 613.36M | 850.62M | 725.24M | 893.38M | 1.06B | 1.15B | 1.27B | 1.35B | 1.42B | 1.52B | 1.62B | 1.75B |
| Cash & Equivalents | 22.06M | 37.86M | 22.88M | 36.51M | 20.28M | 35.47M | 76.82M | 82.48M | 52.12M | 44.10M | 25.57M | - | - | - | 24.27M | 23.67M | 46.54M | 17.16M |
| Long Term Debt | - | - | 220.63M | 235.95M | 225.41M | 197.50M | 175.36M | 1.69B | 1.70B | 1.58B | 888.01M | 777.27M | 693.76M | 812.88M | 907.07M | 959.92M | 980.15M | 1.19B |
| Total Liabilities | - | - | 350.15M | 414.06M | 409.01M | 348.65M | 341.76M | 2.13B | 2.11B | 1.95B | 1.27B | 1.20B | 1.10B | 1.23B | 1.38B | 1.42B | 1.46B | 1.66B |
| Current Liabilities | - | - | 60.59M | 94.05M | 91.76M | 91.80M | 108.66M | 213.84M | 185.22M | 209.00M | 164.57M | 179.08M | 156.19M | 159.63M | 223.75M | 220.97M | 227.17M | 232.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 71.77M | 76.89M | 89.92M | 64.83M | 56.76M | 81.28M | 12.48M | 105.53M | 149.36M | 167.30M | 165.36M | 181.34M | 156.67M | 116.38M | 180.21M | 205.21M | 196.15M |
| Investing Cash Flow | -21.14M | -13.92M | -80.39M | -59.79M | -18.28M | -35.92M | -473.56M | -63.30M | -47.94M | 536.67M | -58.86M | -56.58M | -271.00M | -200.42M | -163.37M | -195.41M | -270.73M |
| Financing Cash Flow | -34.51M | -78.82M | 3.69M | -21.45M | -23.36M | -2.38M | 467.91M | -72.15M | -111.67M | -725.08M | -117.93M | -88.58M | 81.99M | 92.48M | -18.01M | 13.32M | 43.56M |
| Capital Expenditure | -19.67M | -16.14M | -22.49M | -41.07M | -18.86M | -24.83M | -44.62M | -58.63M | -47.30M | -44.91M | -48.20M | -46.83M | -53.46M | -74.73M | -119.94M | -105.36M | -91.03M |
| Free Cash Flow | 52.09M | 60.74M | 67.43M | 23.76M | 37.90M | 56.45M | -32.14M | 46.90M | 102.06M | 122.39M | 117.16M | 134.51M | 103.20M | 41.65M | 60.27M | 99.85M | 105.12M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 50.01M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 31.9% | 32.5% | 31.7% | 31.2% | 33.0% | 33.6% | 29.4% | 31.4% | 31.2% | 29.8% | 28.2% | 26.6% | - | 26.0% | 26.3% | 26.7% | 27.0% |
| Operating Margin % | 0.2% | 12.9% | 10.8% | 4.0% | 9.2% | 11.0% | 1.6% | 8.6% | 11.1% | 12.8% | 12.5% | 11.2% | - | 9.6% | 11.2% | 12.8% | 12.9% |
| Net Margin % | -1.7% | 6.2% | 5.8% | -0.7% | 5.5% | 8.1% | -0.9% | 0.6% | 5.9% | 13.8% | 7.7% | 7.2% | - | 5.0% | 5.8% | 7.0% | 5.5% |
| ROE % | -2.4% | 7.8% | 7.1% | -1.0% | 6.7% | 9.0% | -0.9% | 0.8% | 7.5% | 15.8% | 8.4% | 6.1% | - | 4.7% | 6.0% | 7.4% | 5.9% |
| ROCE % | - | 9.6% | 7.8% | 3.2% | 7.7% | 8.9% | 0.5% | 3.5% | 4.8% | 7.2% | 7.3% | 5.4% | - | 5.0% | 6.4% | 7.7% | 7.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.75% | 5.35M | $670.98M |
| 2 | Invesco Ltd. | 6.61% | 2.25M | $281.62M |
| 3 | Vanguard Portfolio Management LLC | 6.00% | 2.04M | $255.73M |
| 4 | Dimensional Fund Advisors LP | 4.79% | 1.63M | $204.01M |
| 5 | Nomura Holdings Inc. | 4.57% | 1.55M | $194.82M |
| 6 | Vanguard Capital Management LLC | 4.51% | 1.53M | $191.99M |
| 7 | State Street Corporation | 4.16% | 1.41M | $177.11M |
| 8 | Morgan Stanley | 3.96% | 1.35M | $168.66M |
| 9 | Irenic Capital Management LP | 3.72% | 1.26M | $158.45M |
| 10 | Earnest Partners LLC | 2.97% | 1.01M | $126.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ITGR
ITGR Stock Alert: Halper Sadeh LLC is Investigating Whether Integer Holdings Corporation is Obtaining a Fair Price for its Shareholders - daily-tribune.com
<a href="https://news.google.com/rss/articles/CBMiuAJBVV95cUxNNXJzbjNpakl3TFVTdDVoYnJCcGFEZEtPRDU4TEhqdGEzTTBMTVV0OUdBc0lYQ09PSG1VWk40SHpDWkgtQXZ4UDNwZHBwX2tIdS1rRWFjN1F3aHV1TWZKZFZpWHFlQXNZOHQ0aFFza0h3VWhMVVEyMnRMWG4zc25NYy1IM0xrcTZiLXg3NE…
How Could KKR's $5.7 Billion Buyout Reshape ITGR for Shareholders? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNVkJvdWNnVHZsTUlwNl9Jb2hxc1c5UTVxVjJCNFlhUE94bFZRRmlzZllFeHdaYWRVSEE5Z3dDWUtMZkZLUzVxQldSTUdPcFBRbC1vRjVFN0tDZ3JzbEhCam5wSVJueDYwc0ktSFQtcHE0R1hudWduakwzZl9CenJNNGZTVUNibmg1WHNxN1…
ITGR Stock Alert: Halper Sadeh LLC is Investigating Whether Integer Holdings Corporation is Obtaining a Fair Price for its Shareholders - FinancialContent
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxPQjBzY0JIRTNrQXRsSEl5Y09pSXczSVZuYWdiaS1PXzNwSVBTRFAyRmc2RlZxcXhTdlIyWDRPcXBRS2pDc1RWQlU5V2QwZThmdnNmTGR6a29Yd21SdDlTZFV3MVZDUThSeXlORTdXS3UyWVpBYXdQUGZkSUxVemhmWU95QkR2S2VqUkl1ZU…
Integer Holdings (ITGR) Stock Looks Below Fair Value On Cash Flow But Above Fair Value On Earnings - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPRXJCMHdCeFpJUXBEWmdrSWhTZEJ1WVQxS0tIUnByTjlzTVBFN1hJb0ZQMkFGVjZRMkxoM2I0bHgwYmhXU2NyaUFvMEt2SEZlR2tab3BfZGM3d3UyTE9LbXpWa2JtTlBZRklUTTRJSWQzdFJ2TEtXRG9LWGZ6WUdjTjEwNmVnOG1Tc3dNTl…
Integer Holdings (ITGR) Stock Is Up, What You Need To Know - StockStory
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOM1BYV2VDTm1yREg4NkRpRjA1T1VOWURfWWF0dXMxTE5ycVgzaldreVh3WkdyZDhucHJtZDV2N1kwdGFaVnZoZlY2SkRhRllTOFJ4SXRuMVJGcmNIdWRGSllGQ1FsLTU1ZTBOMGZFM0NmRXZaS0xBN203RDEtX2paUTh4U2h1alpTUHoyVm…
ITGR Stock Alert: Halper Sadeh LLC is Investigating Whether Integer Holdings Corporation is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxNVHBVcjJubHlBbjR2THNuRk4xSWdaaFZubFlRZDhVcmFrXzhoUDVOZ0FUc1ozT0N5VUdEaVNzdEk3QkZkc3dXUlBpLUdfQXROYnMxSUU0QlBkVlpzMDZ0UEpSODVweDNhd0s0aFkzYlZiZHh0ekgtVllYTHIwMndXQ2w3MlRsR0Q5WEpWeV…
ITGR — Frequently Asked Questions
What is the current share price of Integer Holdings Corporation (ITGR)?
As of 2026-09-07 16:24 PDT, Integer Holdings Corporation (ITGR) trades at $126.50 on NYSE. Its 52-week range is $63.32 to $126.50.
What is the market capitalisation of ITGR?
Integer Holdings Corporation (ITGR) has a market capitalisation of $4.30B on NYSE.
What is the P/E ratio of ITGR?
ITGR trades at a trailing price-to-earnings (P/E) ratio of 34.56. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.51.
What is the return on equity (ROE) of ITGR?
ITGR has a return on equity (ROE) of 7.50%. Its return on capital employed (ROCE) is 7.52%.
Is ITGR a good stock to buy?
This page provides a data-driven analysis of Integer Holdings Corporation (ITGR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.